ClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt
Release Date: 08/09/2013

ClinicalTrials.gov ID: NCT00855166

Study Identification

Unique Protocol ID:	D1690C00012
Brief Title:	Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes
Official Title:	A 24-week,Multi-centre,Int.,Double-blind,Rand.,Parallel-group,Plac.-Controlled,Phase III Study With a 78-week Ext.Per. to Evaluate the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone
Secondary IDs:	

Study Status

Record Verification:	August 2013
Overall Status:	Completed
Study Start:	February 2009
Primary Completion:	June 2010 [Actual]
Study Completion:	December 2011 [Actual]

Sponsor/Collaborators

Sponsor:	AstraZeneca
Responsible Party:	Sponsor
Collaborators:	Bristol-Myers Squibb

Oversight

FDA Regulated?:	Yes

Applicable Trial?:	Section 801 Clinical Trial? Yes Delayed Posting? No
IND/IDE Protocol?:	No
Review Board:	Approval Status: Approved Approval Number: 19 December 2008 Board Name: Regionala etikprövningsnämnden i Stockholm Board Affiliation: Curera Hornstull, Stockholm Phone: +40 8-524 864 72 Email: kansli@stockholm.epn.se
Data Monitoring?:	Yes
Plan to Share Data?:	
Oversight Authorities:	Bulgaria: Bulgarian Drug Agency Czech Republic: State Institute for Drug Control Hungary: National Institute of Pharmacy Poland: Ministry of Health Sweden: Medical Products Agency

Study Description

Brief Summary:	This study is being carried out to see if dapagliflozin in addition to metformin decreases body weight and if so, how it compares with metformin alone.
Detailed Description:	

Conditions

Conditions:	Type 2 Diabetes Mellitus
Keywords:	Dapagliflozin Metformin Type 2 diabetes body weight

Study Design

Study Type:	Interventional
Primary Purpose:	Treatment
Study Phase:	Phase 3

Intervention Model:	Parallel Assignment
Number of Arms:	2
Masking:	Double Blind (Subject, Investigator)
Allocation:	Randomized
Endpoint Classification:	Safety/Efficacy Study
Enrollment:	182 [Actual]

Arms and Interventions

Arms	Assigned Interventions
Experimental: A Dapagliflozin 10 mg plus Metformin	Drug: Dapagliflozin Tablet oral 10 mg total daily dose once daily 102 weeks Drug: Metformin Tablet oral 1500 - 2500 mg total daily dose 1-3 times a day104 weeks Drug: Sitagliptin Tablet oral 100 mg total daily dose once daily rescue medication
Placebo Comparator: B Placebo plus Metformin	Drug: Metformin Tablet oral 1500 - 2500 mg total daily dose 1-3 times a day104 weeks Drug: Sitagliptin Tablet oral 100 mg total daily dose once daily rescue medication Drug: Placebo Matching placebo for dapagliflozin, tablet, oral, once daily, 102 weeks

Outcome Measures

[See Results Section.]

Eligibility

Minimum Age:	30 Years
Maximum Age:	75 Years
Gender:	Both
Accepts Healthy Volunteers?:	No
Criteria:	Inclusion Criteria:

- Type 2 diabetes
- Ongoing treatment with metformin on a stable dose of ≥1500 mg/day for at least 12 weeks prior to enrolment
- Inadequate glycemic control, defined as HbA1c ≥6.5% and ≤8.5%

- ≥30 years for males
- ≥55 years for females

Exclusion Criteria:

- Type 1 Diabetes
- Body weight change >5% within 3 months prior to enrolment
- Renal and liver impairment

Contacts/Locations

Study Officials: Jan Bolinder, MD, PhD
Study Principal Investigator
Dept of Endocrinology, Metabolism and Diabetes Karolinska University Hospital Huddinge Karolinska Institutet 141 86 Stockholm
Sweden

Locations: Bulgaria
Research Site
Blagoevgrad, Bulgaria

Research Site
Sofia, Bulgaria

Czech Republic
Research Site
Beroun, Czech Republic

Research Site
Brno, Czech Republic

Research Site
Brno - Kralovo Pole, Czech Republic

Research Site
Praha, Czech Republic

Research Site
Semily, Czech Republic

Research Site
Slany, Czech Republic

Hungary
Research Site
Balatonfured, Hungary

Research Site
Budapest, Hungary

Research Site
Csongrad, Hungary

Research Site
Kecskemet, Hungary

Research Site
TAT, Hungary

Poland
Research Site
Elblag, Poland

Research Site
Krakow, Poland

Research Site
Lublin, Poland

Research Site
Torun, Poland

Research Site
Wroclaw, Poland

Sweden
Research Site
Goteborg, Sweden

Research Site
Jarfalla, Sweden

Research Site
Lund, Sweden

Research Site
Malmo, Sweden

Research Site
Stockholm, Sweden

Research Site
Uppsala, Sweden

References

Citations:

Links:

Study Data/Documents:

Study Results

Participant Flow

Recruitment Details	First participant enrolled: 13 Feb 2009. Last participant completed 24 week period: 03 Jun 2010. 314 participants were enrolled, 182 were randomized in 40 centers in 5 European countries. Men aged 30-75 years and women aged 55-75 years with inadequate glycemic control (HbA1c 6.5% to 8.5%), BMI of at least 25 kg/ sqm and body weight <= 120 kg.
Pre-Assignment Details	During a placebo lead-in period, participants were counselled on dietary and life-style modifications. The metformin dose was adjusted to open label 1500 mg/day, 2000 mg/day or 2500 mg/day. Neither gender should exceed 60% of the total number of randomized participants.

Reporting Groups

	Description
Placebo Plus Metformin	Placebo oral once daily plus metformin over 24 weeks
Dapagliflozin Plus Metformin	Dapagliflozin 10 mg oral once daily plus metformin over 24 weeks

Overall Study

	Placebo Plus Metformin	Dapagliflozin Plus Metformin
Started	91	91 [1]
Completed	86	83
Not Completed	5	8
Adverse Event	0	2
Death	0	1
Withdrawal by Subject	1	4
Poor/non-compliance	2	0

	Placebo Plus Metformin	Dapagliflozin Plus Metformin
Administrative reasons by sponsor	1	0
Subject no longer meets study criteria	1	1

[1] Of the 91 randomized participants only 89 were included in the full analysis set.

Baseline Characteristics

Analysis Population Description

Full Analysis Set defined as all randomized participants (as randomized) who received at least one dose of double-blind study medication, who have a non-missing baseline value and at least one post-baseline efficacy value for at least one efficacy variable during double-blind treatment period.

Reporting Groups

	Description
Placebo Plus Metformin	Placebo oral once daily plus metformin over 24 weeks
Dapagliflozin Plus Metformin	Dapagliflozin 10 mg oral once daily plus metformin over 24 weeks

Baseline Measures

	Placebo Plus Metformin	Dapagliflozin Plus Metformin	Total
Number of Participants	91	89	180
Age, Continuous [units: Years] Mean (Standard Deviation)	60.8 (6.82)	60.6 (8.16)	60.7 (7.49)
Gender, Male/Female [units: Participants]			
Female	40	40	80
Male	51	49	100
Race/Ethnicity, Customized White [units: Participants]	91	89	180
Body Weight [units: Kilogram] Mean (Standard Deviation)	90.91 (13.716)	92.06 (14.128)	91.48 (13.894)
Body Mass Index [units: kg/m2] Mean (Standard Deviation)	31.68 (3.890)	32.06 (3.887)	31.87 (3.882)

	Placebo Plus Metformin	Dapagliflozin Plus Metformin	Total
Glycosylated hemoglobin A1c (HbA1c) [units: Percent] Mean (Standard Deviation)	7.16 (0.531)	7.19 (0.443)	7.17 (0.489)
Fasting Plasma Glucose [units: Milligram per deciliter] Mean (Standard Deviation)	149.60 (25.086)	148.01 (24.650)	148.82 (24.815)

Outcome Measures

1. Primary Outcome Measure:

Measure Title	Adjusted Mean Change in Total Body Weight
Measure Description	To evaluate the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin on total body weight after 24 weeks of oral administration of double-blind treatment.
Time Frame	Baseline to Week 24
Safety Issue?	No

Analysis Population Description

Full Analysis Set, participants with non-missing baseline and Week 24 (LOCF) values

Reporting Groups

	Description
Placebo Plus Metformin	Placebo oral once daily plus metformin over 24 weeks
Dapagliflozin Plus Metformin	Dapagliflozin 10 mg oral once daily plus metformin over 24 weeks

Measured Values

	Placebo Plus Metformin	Dapagliflozin Plus Metformin
Number of Participants Analyzed	91	89
Adjusted Mean Change in Total Body Weight [units: kg] Least Squares Mean (95% Confidence Interval)	-0.88 (-1.43 to -0.34)	-2.96 (-3.51 to -2.41)

Statistical Analysis 1 for Adjusted Mean Change in Total Body Weight

Statistical Analysis Overview	Comparison Groups	Placebo Plus Metformin, Dapagliflozin Plus Metformin
	Comments	H0: mean(treat) minus mean(placebo) = 0 versus the alternative HA: mean(treat) minus mean(placebo) =/= 0
	Non-Inferiority or Equivalence Analysis?	No
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.0001
	Comments	Significant at alpha=0.05 (2-sided)
	Method	ANCOVA
	Comments	with treatment group and stratum (gender) as effects and baseline value as covariate

Method of Estimation	Estimation Parameter	Mean Difference (Final Values)
	Estimated Value	-2.08
	Confidence Interval	(2-Sided) 95% -2.84 to -1.31
	Parameter Dispersion	Type: Standard Error of the mean Value: 0.3885
	Estimation Comments	[Not specified]

2. Secondary Outcome Measure:

Measure Title	Adjusted Mean Change in Waist Circumference
Measure Description	To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 24 weeks of double-blind treatment on waist circumference.
Time Frame	Baseline to Week 24
Safety Issue?	No

Analysis Population Description

Full Analysis Set, participants with non-missing baseline and Week 24 (LOCF) values

Reporting Groups

	Description
Placebo Plus Metformin	Placebo oral once daily plus metformin over 24 weeks

	Description
Dapagliflozin Plus Metformin	Dapagliflozin 10 mg oral once daily plus metformin over 24 weeks

Measured Values

	Placebo Plus Metformin	Dapagliflozin Plus Metformin
Number of Participants Analyzed	91	89
Adjusted Mean Change in Waist Circumference [units: cm] Least Squares Mean (95% Confidence Interval)	-0.99 (-1.84 to -0.13)	-2.51 (-3.38 to -1.64)

Statistical Analysis 1 for Adjusted Mean Change in Waist Circumference

Statistical Analysis Overview	Comparison Groups	Placebo Plus Metformin, Dapagliflozin Plus Metformin
	Comments	H0: mean(treat) minus mean(placebo) = 0 versus the alternative HA: mean(treat) minus mean(placebo) =/= 0
	Non-Inferiority or Equivalence Analysis?	No
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.0143
	Comments	Significant at alpha=0.05 (2-sided). Results of key secondary endpoints are interpreted using Hochberg's method
	Method	ANCOVA
	Comments	with treatment group and stratum (gender) as effects and baseline value as covariate

Method of Estimation	Estimation Parameter	Mean Difference (Final Values)
	Estimated Value	-1.52
	Confidence Interval	(2-Sided) 95% -2.74 to -0.31
	Parameter Dispersion	Type: Standard Error of the mean Value: 0.6162
	Estimation Comments	[Not specified]

3. Secondary Outcome Measure:

Measure Title	Adjusted Mean Change in Body Fat Mass
Measure Description	To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 24 weeks of double-blind treatment on total body fat mass measured by dual energy X-ray absorptiometry.
Time Frame	Baseline to Week 24
Safety Issue?	No

Analysis Population Description

Full Analysis Set, participants with non-missing baseline and Week 24 (LOCF) values

Reporting Groups

	Description
Placebo Plus Metformin	Placebo oral once daily plus metformin over 24 weeks
Dapagliflozin Plus Metformin	Dapagliflozin 10 mg oral once daily plus metformin over 24 weeks

Measured Values

	Placebo Plus Metformin	Dapagliflozin Plus Metformin
Number of Participants Analyzed	79	82
Adjusted Mean Change in Body Fat Mass [units: kg] Least Squares Mean (95% Confidence Interval)	-0.74 (-1.27 to -0.22)	-2.22 (-2.74 to -1.70)

Statistical Analysis 1 for Adjusted Mean Change in Body Fat Mass

Statistical Analysis Overview	Comparison Groups	Placebo Plus Metformin, Dapagliflozin Plus Metformin
	Comments	H0: mean(treat) minus mean(placebo) = 0 versus the alternative HA: mean(treat) minus mean(placebo) =/= 0
	Non-Inferiority or Equivalence Analysis?	No
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.0001
	Comments	Significant at alpha=0.05 (2-sided). Results of key secondary endpoints are interpreted using Hochberg's method

	Method	ANCOVA
	Comments	with treatment group and stratum (gender) as effects and baseline value as covariate

Method of Estimation	Estimation Parameter	Mean Difference (Final Values)
	Estimated Value	-1.48
	Confidence Interval	(2-Sided) 95% -2.22 to -0.74
	Parameter Dispersion	Type: Standard Error of the mean Value: 0.3731
	Estimation Comments	[Not specified]

4. Secondary Outcome Measure:

Measure Title	Proportion of Participants With Body Weight Decrease ≥5%
Measure Description	To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 24 weeks of double-blind treatment on body weight decrease ≥5%. Least Squares Mean represents the percent of participants adjusted for body weight baseline value.
Time Frame	Baseline to Week 24
Safety Issue?	No

Analysis Population Description

Full Analysis Set, participants with non-missing baseline and Week 24 (LOCF) values

Reporting Groups

	Description
Placebo Plus Metformin	Placebo oral once daily plus metformin over 24 weeks
Dapagliflozin Plus Metformin	Dapagliflozin 10 mg oral once daily plus metformin over 24 weeks

Measured Values

	Placebo Plus Metformin	Dapagliflozin Plus Metformin
Number of Participants Analyzed	91	89
Proportion of Participants With Body Weight Decrease ≥5% [units: Percentage of participants] Least Squares Mean (95% Confidence Interval)	4.3 (0.1 to 8.6)	30.6 (21.1 to 40.2)

Statistical Analysis 1 for Proportion of Participants With Body Weight Decrease ≥5%

Statistical Analysis Overview	Comparison Groups	Placebo Plus Metformin, Dapagliflozin Plus Metformin
	Comments	H0: proportion(treat) minus proportion(placebo) = 0 versus the alternative HA: proportion(treat) minus proportion(placebo) =/= 0
	Non-Inferiority or Equivalence Analysis?	No
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.0001
	Comments	Significant at alpha=0.05 (2-sided). Results of key secondary endpoints are interpreted using Hochberg's method
	Method	Regression, Logistic
	Comments	Based on methodology of Zhang, Tsiatis & Davidian and Davidian, Tsiatis, Zhang & Lu, with adjustment for baseline value and stratum (gender).

Method of Estimation	Estimation Parameter	Risk Difference (RD)
	Estimated Value	26.3
	Confidence Interval	(2-Sided) 95% 15.9 to 36.7
	Parameter Dispersion	Type: Standard Error of the mean Value: 5.309
	Estimation Comments	[Not specified]

5. Other Pre-specified Outcome Measure:

Measure Title	Adjusted Percent Change in Bone Mineral Density (BMD) at Lumbar Spine (L1-4)
Measure Description	To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 102 weeks of double-blind treatment on Bone Mineral Density at lumbar spine (L1-4) as measured by Dual Energy X-ray Absorptiometry.
Time Frame	Baseline to Week 102
Safety Issue?	Yes

Analysis Population Description

Safety Analysis Set (all participants who received at least one dose of double-blind study medication)

Reporting Groups

	Description
Placebo Plus Metformin	Placebo oral once daily plus metformin over 102 weeks
Dapagliflozin Plus Metformin	Dapagliflozin 10 mg oral once daily plus metformin over 102 weeks

Measured Values

	Placebo Plus Metformin	Dapagliflozin Plus Metformin
Number of Participants Analyzed	71	68
Adjusted Percent Change in Bone Mineral Density (BMD) at Lumbar Spine (L1-4) [units: Percent] Least Squares Mean (95% Confidence Interval)	0.47 (-0.32 to 1.27)	0.69 (-0.19 to 1.57)

Statistical Analysis 1 for Adjusted Percent Change in Bone Mineral Density (BMD) at Lumbar Spine (L1-4)

Statistical Analysis Overview	Comparison Groups	Placebo Plus Metformin, Dapagliflozin Plus Metformin
	Comments	H0: mean(treat) minus mean(placebo) = 0 versus the alternative HA: mean(treat) minus mean(placebo) =/= 0
	Non-Inferiority or Equivalence Analysis?	No
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.7013
	Comments	Exploratory. Model including fixed categorical effects of treatment, week, treatment-by-week interaction, gender and rescue medication as well as continuous fixed covariates of baseline measurement and baseline measurement-by-week interaction.
	Method	Mixed Models Analysis
	Comments	Percent change in BMD from baseline to week 102 evaluated via longitudinal repeated measures analysis using direct likelihood.

Method of Estimation	Estimation Parameter	Mean Difference (Final Values)
	Estimated Value	0.22
	Confidence Interval	(2-Sided) 95% -0.89 to 1.34
	Parameter Dispersion	Type: Standard Error of the mean

		Value: 0.5652
	Estimation Comments	Natural logarithms of baseline and week 102 values were used.

6. Other Pre-specified Outcome Measure:

Measure Title	Adjusted Percent Change in Bone Mineral Density (BMD) at Femoral Neck
Measure Description	To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 102 weeks of double-blind treatment on Bone Mineral Density at femoral neck as measured by Dual Energy X-ray Absorptiometry.
Time Frame	Baseline to Week 102
Safety Issue?	Yes

Analysis Population Description

Safety Analysis Set (all participants who received at least one dose of double-blind study medication)

Reporting Groups

	Description
Placebo Plus Metformin	Placebo oral once daily plus metformin over 102 weeks
Dapagliflozin Plus Metformin	Dapagliflozin 10 mg oral once daily plus metformin over 102 weeks

Measured Values

	Placebo Plus Metformin	Dapagliflozin Plus Metformin
Number of Participants Analyzed	71	68
Adjusted Percent Change in Bone Mineral Density (BMD) at Femoral Neck [units: Percent] Least Squares Mean (95% Confidence Interval)	0.09 (-0.83 to 1.01)	-0.85 (-1.85 to 0.16)

Statistical Analysis 1 for Adjusted Percent Change in Bone Mineral Density (BMD) at Femoral Neck

Statistical Analysis Overview	Comparison Groups	Placebo Plus Metformin, Dapagliflozin Plus Metformin
	Comments	H0: mean(treat) minus mean(placebo) = 0 versus the alternative HA: mean(treat) minus mean(placebo) =/= 0
	Non-Inferiority or Equivalence Analysis?	No
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.1521
	Comments	Exploratory. Model including fixed categorical effects of treatment, week, treatment-by-week interaction, gender and rescue medication as well as continuous fixed covariates of baseline measurement and baseline measurement-by-week interaction.
	Method	Mixed Models Analysis
	Comments	Percent change in BMD from baseline to week 102 evaluated via longitudinal repeated measures analysis using direct likelihood.

Method of Estimation	Estimation Parameter	Mean Difference (Final Values)
	Estimated Value	-0.94
	Confidence Interval	(2-Sided) 95% -2.21 to 0.35
	Parameter Dispersion	Type: Standard Error of the mean Value: 0.6473
	Estimation Comments	Natural logarithms of baseline and week 102 values were used.

7. Other Pre-specified Outcome Measure:

Measure Title	Adjusted Percent Change in Bone Mineral Density (BMD) at Total Hip
Measure Description	To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 102 weeks of double-blind treatment on Bone Mineral Density at total hip as measured by Dual Energy X-ray Absorptiometry.
Time Frame	Baseline to Week 102
Safety Issue?	Yes

Analysis Population Description

Safety Analysis Set (all participants who received at least one dose of double-blind study medication)

Reporting Groups

	Description
Placebo Plus Metformin	Placebo oral once daily plus metformin over 102 weeks
Dapagliflozin Plus Metformin	Dapagliflozin 10 mg oral once daily plus metformin over 102 weeks

Measured Values

	Placebo Plus Metformin	Dapagliflozin Plus Metformin
Number of Participants Analyzed	71	68
Adjusted Percent Change in Bone Mineral Density (BMD) at Total Hip [units: Percent] Least Squares Mean (95% Confidence Interval)	-0.37 (-1.00 to 0.26)	-0.82 (-1.52 to -0.12)

Statistical Analysis 1 for Adjusted Percent Change in Bone Mineral Density (BMD) at Total Hip

Statistical Analysis Overview	Comparison Groups	Placebo Plus Metformin, Dapagliflozin Plus Metformin
	Comments	H0: mean(treat) minus mean(placebo) = 0 versus the alternative HA: mean(treat) minus mean(placebo) =/= 0
	Non-Inferiority or Equivalence Analysis?	No
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.3105
	Comments	Exploratory. Model including fixed categorical effects of treatment, week, treatment-by-week interaction, gender and rescue medication as well as continuous fixed covariates of baseline measurement and baseline measurement-by-week interaction.
	Method	Mixed Models Analysis
	Comments	Percent change in BMD from baseline to week 102 evaluated via longitudinal repeated measures analysis using direct likelihood.

Method of Estimation	Estimation Parameter	Mean Difference (Final Values)
	Estimated Value	-0.45
	Confidence Interval	(2-Sided) 95% -1.32 to 0.43
	Parameter Dispersion	Type: Standard Error of the mean Value: 0.4428
	Estimation Comments	Natural logarithms of baseline and week 102 values were used.

Reported Adverse Events

Time Frame	Non-serious / serious adverse events on or after the first day and on or prior to the last day of the 24-week double-blind treatment plus 4/30 days or up to follow-up visit if earlier, or up to and including the start date of extension period if earlier.
Additional Description	Participants were questioned at each study visit about the occurrence of any health problems and any examination conducted at a study visit was assessed in comparison to the status at study entry.

Reporting Groups

	Description
Placebo Plus Metformin	Placebo oral once daily plus metformin over 24 weeks
Dapagliflozin Plus Metformin	Dapagliflozin 10 mg oral once daily plus metformin over 24 weeks

Serious Adverse Events

	Placebo Plus Metformin	Dapagliflozin Plus Metformin
	Affected/At Risk (%)	Affected/At Risk (%)
Total	1/91 (1.1%)	6/91 (6.59%)
Ear and labyrinth disorders		
Vertigo [A] †	0/91 (0%)	1/91 (1.1%)
Eye disorders		
Ulcerative keratitis [A] †	1/91 (1.1%)	0/91 (0%)
Gastrointestinal disorders		
Oesophageal varices hemorrhage [A] †	0/91 (0%)	1/91 (1.1%)
Infections and infestations		
Pneumonia [A] †	0/91 (0%)	2/91 (2.2%)
Musculoskeletal and connective tissue disorders		
Spinal osteoarthritis [A] †	0/91 (0%)	1/91 (1.1%)
Nervous system disorders		
Transient ischemic attack [A] †	0/91 (0%)	1/91 (1.1%)
Vascular disorders		

	Placebo Plus Metformin	Dapagliflozin Plus Metformin
	Affected/At Risk (%)	Affected/At Risk (%)
Hypertension [A] †	0/91 (0%)	1/91 (1.1%)

† Indicates events were collected by systematic assessment.
A Term from vocabulary, MedDRA 13.0

Other Adverse Events

Frequency Threshold Above Which Other Adverse Events are Reported: 5%

	Placebo Plus Metformin	Dapagliflozin Plus Metformin
	Affected/At Risk (%)	Affected/At Risk (%)
Total	9/91 (9.89%)	7/91 (7.69%)
Infections and infestations		
Nasopharyngitis [A] †	5/91 (5.49%)	6/91 (6.59%)
Musculoskeletal and connective tissue disorders		
Arthralgia [A] †	5/91 (5.49%)	1/91 (1.1%)

† Indicates events were collected by systematic assessment.
A Term from vocabulary, MedDRA 13.0

Limitations and Caveats

For participants who did not complete 24 weeks, last observation carried forward (LOCF) was used.

More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

If an Investigator requests permission to publish data from this study any such publication is to be agreed with AstraZeneca (AZ) in advance. The investigator agrees to provide AZ as soon as possible with drafts of proposed publications. Unless otherwise agreed, AZ shall have a period of 60 days from receipt of the proposed final manuscript to review it and may within such time require that submission for publication of the manuscript be delayed in order for AZ to file patent applications.

Results Point of Contact:

Name/Official Title: Eva Johnsson

Organization: AstraZeneca

Phone:

Email: ClinicalTrialTransparency@astrazeneca.com